Hepatic fibrosis: molecular mechanisms and drug targets.
about
Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future ProspectsCellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosisHow Inflammation Impinges on NAFLD: A Role for Kupffer CellsHrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosisActivation of protein serine/threonine phosphatase PP2Cα efficiently prevents liver fibrosisOral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- miceHepatic stellate cells: protean, multifunctional, and enigmatic cells of the liverLeukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production.Withagulatin A inhibits hepatic stellate cell viability and procollagen I production through Akt and Smad signaling pathways.Enhanced amelioration of high-fat diet-induced fatty liver by docosahexaenoic acid and lysine supplementationsPAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division.Effect of WeiJia on carbon tetrachloride induced chronic liver injuryENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice.Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin AHepatoprotective effects of Limonium tetragonum, edible medicinal halophyte growing near seashoresRecent advances in the understanding of the role of the endocannabinoid system in liver diseases.Combined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors.Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion.The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsInfluence of cannabis use on severity of hepatitis C diseaseStudy on the Antifibrotic Effects of Recombinant Shark Hepatical Stimulator Analogue (r-sHSA) in Vitro and in Vivo.Understanding the mechanism of hepatic fibrosis and potential therapeutic approachesMononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis.Proteomic analysis of the effect of fuzheng huayu recipe on fibrotic liver in ratsCannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.Nuclear cathepsin F regulates activation markers in rat hepatic stellate cellsCB2 receptors as new therapeutic targets for liver diseasesNew role of plasminogen activator inhibitor-1 in alcohol-induced liver injury.Moniliformediquinone as a potential therapeutic agent, inactivation of hepatic stellate cell and inhibition of liver fibrosis in vivo.Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism.Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis.Antifibrotic effects of green tea on in vitro and in vivo models of liver fibrosis.The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm.Retinyl ester hydrolases and their roles in vitamin A homeostasis.Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Autophagy: a multifaceted partner in liver fibrosis.Effect of reversine on cell cycle, apoptosis, and activation of hepatic stellate cells.New role and molecular mechanism of Gadd45a in hepatic fibrosis.The histological quantification of alpha-smooth muscle actin predicts future graft fibrosis in pediatric liver transplant recipients.
P2860
Q26775055-F6AEFF81-6FFE-48A8-8ADA-80CD70C6B976Q27021577-A2CCDAE5-5C51-439A-8D53-8F398BA016A6Q28083001-41C9568D-7514-4BAF-92FD-9F9D637107C7Q28385517-D58DB52E-4012-4337-BC68-099CC28167C0Q28476430-43D73882-5BFE-44D0-8C11-C9328AF8F368Q28476642-16DDDFC3-9ED2-449A-BE1E-57F83E0F5E58Q29616840-AE8A74AD-0C66-4EB1-9665-96139125BEBCQ33557476-6A8A7CD7-A97A-436A-95DD-B157485D3BE8Q33557875-978F6C97-C4F7-4DCF-98E1-0FCEA35689A5Q33748530-E7E3A756-2D4B-4BCA-B614-8EF1F68C4620Q33840622-0E5CB62F-26A4-4B70-9BFE-299A04747535Q33866594-995527B1-893F-4B6A-B236-B5D8722C3756Q33906152-B97D9E4B-751A-4A40-9188-E431C29688F3Q34193125-106448A5-A14B-410A-974F-D1A47F7137A4Q34304547-EBBCB5A8-CBA3-4338-AE45-62B274DEB477Q34550846-FA3A5399-94A4-473B-BE95-710963354FE0Q35017823-55B58CD8-1D0E-42F9-83CB-C2549CE25DD7Q35126638-2794DB8B-FA0E-4A85-BF08-89D8B91EFDA5Q35193292-5F561562-1B2E-4329-B4AE-272BAEAD3F0AQ35250832-21A6C40F-BC9C-4684-8185-C062710FFA6EQ36018045-4FE9AD03-3ADF-4F77-ABA7-1392FC25A54BQ36020916-072B0B10-7238-465E-983E-36A407116626Q36446987-A772FF3D-3C25-47D2-873D-6B567A2DBC12Q36602953-DAA8567B-32D6-46C5-94C5-CCA0D77A36EAQ36734955-A3F71327-206B-4E41-AB71-9DCA16EC1030Q36914323-2C496DFA-8008-47D8-8DFA-9EB78094CA45Q36977545-C58B4E80-8D0C-41B9-AE4F-73CD7DEC787CQ37108878-A1E46CD1-9FE8-4B38-AFF4-119C9D50E4BDQ37243925-AD38B83F-AA48-4291-8AF8-685D2F7249AEQ37305691-541F696C-0007-4D4E-A69A-ED3918F464D0Q37368758-A4DFAF37-D4F6-49AB-B160-59DCB1945842Q37413329-BEC160F0-A4D9-4A16-AF7B-27C2F2023400Q37646912-B6688087-7CB2-4EB3-8DE3-FA619CE0EC41Q37876526-0C061FCD-D599-4097-9762-5DE5DD43B9B0Q37978790-30A1743F-1C4C-42AD-B856-D78103741D35Q38124458-B29DC4BE-2C67-47ED-B6DE-52559AF79D73Q38254156-DEA3B48B-3FBD-42AB-99FD-00D507A98966Q38733868-A309CD56-DD67-49AE-8DCB-556BE3D0144CQ38773619-EAFD4E55-AD18-431A-8817-B2D48D96A51DQ38806808-A079505E-7206-4569-8423-5E351AAD92CE
P2860
Hepatic fibrosis: molecular mechanisms and drug targets.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Hepatic fibrosis: molecular mechanisms and drug targets.
@ast
Hepatic fibrosis: molecular mechanisms and drug targets.
@en
type
label
Hepatic fibrosis: molecular mechanisms and drug targets.
@ast
Hepatic fibrosis: molecular mechanisms and drug targets.
@en
prefLabel
Hepatic fibrosis: molecular mechanisms and drug targets.
@ast
Hepatic fibrosis: molecular mechanisms and drug targets.
@en
P2093
P1476
Hepatic fibrosis: molecular mechanisms and drug targets.
@en
P2093
Ariane Mallat
Boris Julien
Fatima Teixeira-Clerc
Pascale Grenard
P304
P356
10.1146/ANNUREV.PHARMTOX.45.120403.095906
P577
2005-01-01T00:00:00Z